重组人血管内皮抑素联合化疗治疗进展期胃癌的初步研究

目的探讨应用重组人血管内皮抑素联合OLF方案化疗对进展期胃癌术后生活质量和生存期的影响。方法将68例进展期胃癌术后患者随机分为两组：化疗组34例,采用OLF方案,奥沙利铂130mg/m2d1,甲酰四氢叶酸200mg/m2d1-5,5-氟脲嘧啶400mg/m2d1-5,3周为1个周期;靶向治疗组34例,化疗方案同化疗组并于每周期化疗第1天开始给予恩度7.5mg/m2,静脉滴注,每日1次,连用14d为1个疗程,间歇7d,重复使用。结果两组1年生存率分别为79.4%、85.3%,差异无统计学意义（P〉0.05）;3年生存率分别为32.4%、52.3%,差异有统计学意义（P〈0.05）。两组生活质量改善率分别为61.8%（21/34）、82.4%（28/34）,差异有统计学意义（P〈0.05）。结论进展期胃癌术后应用重组人血管内皮抑素联合化疗可提高患者生活质量,延长生存时间。

A Preliminary Study of Endostar Combined with Chemotherapy on Advanced Gastric Cancer

Objective To investigate the effect of rh-endostar injection combined with OLF chemotherapy on quality of life and survival period in postoperative patients with advanced gastric cancer. Methods Sixty-eight patients with advanced gastric cancer were divided into two groups：OLF group was（34 cases）treated with oxaliplatin 130mg/m2, d1;leucovorin 200mg/m2, d1-5; 5-FU 400mg/m2 iv d1-5 every 21 days for 4 cycles. Targeted therapy group（34 cases）was treated with YH-16 7.5mg/m2 （day1-14） and OLF in the same therapeutic cycles. Results The one-year survival rates in the two groups were 79.4%, 85.3% without any significant difference（P0.05）. The three-year survival rates were 32.4%, 52.3% respectively. The three-year survival rate of targeted therapy group was significantly higher than that of OLF group（P0.05）. The quality of life improvement rate in the two groups were 61.8%（21/34）, 82.4%（28/34） and the difference was statistically significant（P0.05）. Conclusion rh-endostar injection combined with OLF chemotherapy can enhance the quality of life and prolong survival time of the postoperative patients with advanced gastric cancer.